CJC-1295 No DAC + GHRP-6 – 5mg/5mg (3ml Pen)

CJC-1295 No DAC + GHRP-6 is a dual-peptide research formulation combining a growth hormone-releasing hormone (GHRH) analogue with a synthetic growth hormone secretagogue. Supplied in a 3ml pen containing 5mg of each compound, this combination is studied for its interaction with pituitary signalling, growth hormone secretion and metabolic pathways associated with muscle physiology.

The formulation combines two distinct mechanisms of action. CJC-1295 No DAC interacts with GHRH receptors, while GHRP-6 activates ghrelin receptors (GHS-R1a). Research into these complementary pathways has demonstrated that their simultaneous activation can generate a greater growth hormone response than either pathway alone.

This makes the combination relevant to scientific investigations into endocrine regulation, protein metabolism and the biological processes involved in tissue development.

Growth Hormone and Muscle Development Research

Growth hormone contributes to several physiological processes, including protein metabolism, tissue development and the regulation of energy balance.

CJC-1295 No DAC and GHRP-6 are of particular interest in studies examining how different receptor systems influence growth hormone secretion and downstream biological signalling.

Research involving these compounds focuses on several areas:

• Growth hormone secretion: Investigating how simultaneous GHRH and ghrelin receptor activation influences pituitary hormone release.
• Muscle physiology: Examining endocrine signalling pathways associated with muscle tissue development and protein metabolism.
• Metabolic regulation: Studying hormonal mechanisms involved in energy balance and nutrient metabolism.
• Appetite signalling: Exploring the effects of GHRP-6 on hypothalamic feeding pathways.
• Hormonal interactions: Understanding the relationship between growth hormone secretion, somatostatin activity and ghrelin receptor stimulation.

Although these pathways are associated with muscle development, evidence establishing that this specific combination directly improves muscle mass, strength or athletic performance in humans remains limited.

For researchers exploring related compounds, Coridion Sciences offers a wider range of growth and performance research peptides, including formulations investigated for growth hormone signalling, muscle physiology and metabolic processes.

Mechanisms of Action

CJC-1295 No DAC – GHRH Receptor Activation

CJC-1295 No DAC is a modified analogue of growth hormone-releasing hormone, developed to improve resistance to enzymatic degradation.

It activates GHRH receptors in the anterior pituitary, stimulating intracellular cAMP signalling associated with growth hormone secretion.

Unlike longer-acting DAC-containing analogues, CJC-1295 No DAC has a shorter duration of activity, making it relevant to research examining pulsatile growth hormone release.

GHRP-6 – Ghrelin Receptor Signalling

GHRP-6 is a synthetic growth hormone secretagogue that activates the ghrelin receptor GHS-R1a.

Its mechanism differs from that of GHRH analogues, involving alternative intracellular signalling pathways that influence growth hormone secretion.

GHRP-6 has also demonstrated pronounced appetite-related activity in experimental research, distinguishing it from more selective growth hormone secretagogues.

Combined Receptor Activity

Research investigating the simultaneous activation of GHRH and ghrelin receptors has reported synergistic effects on growth hormone secretion.

One proposed explanation involves the interaction between stimulatory signalling and somatostatin-mediated inhibition of pituitary hormone release.

However, evidence for the specific CJC-1295 No DAC + GHRP-6 fixed-dose formulation is less extensive than the research supporting these individual signalling mechanisms.

Research Status and Scientific Findings

Growth Hormone Pathway Synergy

Studies involving GHRH analogues and growth hormone secretagogues have demonstrated that activating both receptor systems can produce a greater growth hormone response than activating either system independently.

Somatostatin Regulation

Somatostatin acts as an inhibitory regulator of growth hormone secretion. Ghrelin receptor agonists may influence this regulatory system, contributing to their effects on pituitary signalling.

Appetite and Energy Balance

GHRP-6 has been investigated for its influence on hypothalamic appetite-regulating circuits. Animal research has identified feeding-related responses associated with ghrelin receptor activation.

Endocrine Selectivity

GHRP-6 may influence additional hormonal pathways, including cortisol and prolactin responses. These effects are important when interpreting experimental findings involving growth hormone secretagogues.

Muscle Growth and Performance Research

Growth hormone signalling is relevant to muscle tissue physiology, but increased growth hormone secretion does not necessarily translate into improvements in muscle strength, recovery or physical performance.

Further controlled studies would be necessary to establish the effects of this specific combination on those outcomes.

Product Research Characteristics

• Compound: CJC-1295 No DAC + GHRP-6
• Quantity: 5mg + 5mg
• Format: 3ml pen
• Classification: GHRH analogue and growth hormone secretagogue
• Primary research focus: Growth hormone secretion and pituitary signalling
• Additional research areas: Muscle physiology, endocrine regulation, appetite and metabolism
• Receptor activity: GHRH receptor and GHS-R1a

Research Peptides from Coridion Sciences

Coridion Sciences is a specialist supplier of research peptides and advanced peptide delivery systems, offering individual compounds and optimised combinations for laboratory investigation.

The company’s catalogue includes compounds studied for growth hormone regulation, cellular signalling, metabolic processes and tissue physiology.

Research Use Only: CJC-1295 No DAC + GHRP-6 is intended exclusively for scientific and laboratory research. It is not approved for human consumption, therapeutic applications or athletic performance enhancement.

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

Ipamorelin selectivity

Consistently replicated findings of minimal cortisol, ACTH and prolactin involvement.

Pulsatility

Short half-life of the GHRH component preserves the endogenous secretion pattern.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.